↓ Skip to main content

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs

Overview of attention for article published in Clinical Cancer Research, September 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
31 news outlets
blogs
3 blogs
twitter
4 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs
Published in
Clinical Cancer Research, September 2016
DOI 10.1158/1078-0432.ccr-16-0638
Pubmed ID
Authors

Gwynn Ison, Julia A. Beaver, W. David McGuinn, Todd R. Palmby, Jeannette Dinin, Rosane Charlab, Anshu Marathe, Runyan Jin, Qi Liu, Xiao Hong Chen, Xavier Ysern, Olen Stephens, Ge Bai, Yaning Wang, Sarah E. Dorff, Joyce Cheng, Shenghui Tang, Rajeshwari Sridhara, William Pierce, Amy E. McKee, Amna Ibrahim, Geoffrey Kim, Richard Pazdur

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 48 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 14%
Researcher 6 12%
Student > Ph. D. Student 6 12%
Other 4 8%
Professor 4 8%
Other 9 18%
Unknown 13 27%
Readers by discipline Count As %
Medicine and Dentistry 14 29%
Pharmacology, Toxicology and Pharmaceutical Science 8 16%
Biochemistry, Genetics and Molecular Biology 4 8%
Nursing and Health Professions 2 4%
Chemistry 2 4%
Other 4 8%
Unknown 15 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 254. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#147,230
of 25,651,057 outputs
Outputs from Clinical Cancer Research
#64
of 13,281 outputs
Outputs of similar age
#2,919
of 330,409 outputs
Outputs of similar age from Clinical Cancer Research
#3
of 134 outputs
Altmetric has tracked 25,651,057 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,281 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,409 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 134 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.